Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

NCT07137416 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

36

Enrollment

NIH

Sponsor class

Conditions

Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Invasive Breast Carcinoma
Locally Advanced Breast Carcinoma
Metastatic Breast Carcinoma
Metastatic HER2-Low Breast Carcinoma
Metastatic HER2-Positive Breast Carcinoma
Metastatic Hormone Receptor-Positive Breast Carcinoma
Metastatic Malignant Solid Neoplasm
Metastatic Triple-Negative Breast Carcinoma
Unresectable Breast Carcinoma
Unresectable HER2-Low Breast Carcinoma
Unresectable HER2-Positive Breast Carcinoma
Unresectable Hormone Receptor-Positive Breast Carcinoma
Unresectable Malignant Solid Neoplasm
Unresectable Triple-Negative Breast Carcinoma

Interventions

PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
PROCEDURE: Echocardiography Test
PROCEDURE: Multigated Acquisition Scan
DRUG: Pidnarulex
PROCEDURE: Radiologic Imaging Procedure
BIOLOGICAL: Trastuzumab Deruxtecan

Sponsor

National Cancer Institute (NCI)